Advertisement
AMLX vs JAZZ
Which Stock Would AI Choose? Amylyx Pharmaceuticals (AMLX) vs. Jazz Pharmaceuticals (JAZZ) Stock Comparison
Key Takeaways
- AMLX is a clinical-stage biopharmaceutical company focused on neurodegenerative and endocrine conditions, with a market capitalization of approximately $2.26 billion as of late July 2026.
- JAZZ is a commercial-stage biopharmaceutical company with approved products in neuroscience and oncology, reporting trailing twelve-month revenue of $4.44 billion and a market capitalization of about $15.88 billion.
- Both stocks have delivered strong year-to-date returns through recent market activity, with AMLX showing approximately 68% and JAZZ around 49%.
- JAZZ maintains a broader revenue base and upcoming quarterly earnings release, while AMLX advances late-stage pipeline candidates with an earnings update scheduled shortly after.
- Relative positioning highlights trade-offs between AMLX’s higher-beta growth profile tied to clinical catalysts and JAZZ’s more established commercial operations and diversified product portfolio.
Introduction
This comparison examines AMLX and JAZZ within the biotechnology and pharmaceutical sectors. Both companies operate in areas with significant unmet medical needs, yet they differ markedly in stage of development, revenue generation, and market positioning. The analysis focuses on recent performance trends, business fundamentals, and observable market factors to provide traders and investors with a clear framework for evaluating relative opportunities. Institutional and retail participants seeking exposure to healthcare innovation or established specialty pharma may find the contrast between a clinical-stage developer and a commercial-stage leader particularly relevant for portfolio construction and risk assessment.
AMLX Overview and Recent Performance
Amylyx Pharmaceuticals, Inc. is a clinical-stage company developing therapies for neurodegenerative diseases and endocrine disorders. Its pipeline includes candidates such as Avexitide, a GLP-1 receptor antagonist in Phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism, along with programs targeting progressive supranuclear palsy and amyotrophic lateral sclerosis. In recent market activity, AMLX shares traded near $20.31 with a market capitalization of roughly $2.26 billion. The stock recorded a year-to-date return of approximately 68% and a one-year return exceeding 150%, reflecting positive sentiment around pipeline progress and trial enrollment updates. Broader market conditions and sector rotation in healthcare have influenced price behavior, with analysts maintaining an Outperform rating and raising price targets in recent weeks.
JAZZ Overview and Recent Performance
Jazz Pharmaceuticals plc is a commercial-stage biopharmaceutical company with approved products spanning neuroscience and oncology, including Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex for certain seizure disorders, and Zepzelca for small cell lung cancer. The company reported trailing twelve-month revenue of $4.44 billion. As of late July 2026, JAZZ shares closed near $252.86, corresponding to a market capitalization of approximately $15.88 billion. Recent performance includes a year-to-date return of about 49% and a one-year return near 121%, supported by strong first-quarter results and regulatory developments such as priority review for zanidatamab. Upcoming second-quarter earnings on August 3, 2026, and a PDUFA target date of August 25, 2026, for a key supplemental application represent near-term focal points for market participants.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a platform that offers hundreds of bots trading thousands of different tickers. Only those demonstrating the strongest alignment with prevailing market conditions and robust statistical profiles earn placement in this curated section. Available bots span a wide range of trading styles, strategies, timeframes, performance metrics, and ticker universes, with many exhibiting win rates, profit factors, and drawdown statistics that can be reviewed in detail. This diversity allows users to identify tools suited to specific risk tolerances and market environments. For further exploration of these AI-driven trading solutions, visit the Trending AI Robots page.
Head-to-Head Comparison
AMLX operates as a clinical-stage entity with no approved products and negative trailing earnings, emphasizing pipeline catalysts in rare disease areas, whereas JAZZ generates substantial revenue from multiple commercial assets across neuroscience and oncology. Growth drivers for AMLX center on Phase 3 readouts and potential future launches, introducing higher binary risk, while JAZZ benefits from established sales, recurring revenue, and ongoing label expansions. Recent momentum has favored both, yet AMLX exhibits greater price volatility consistent with its smaller market capitalization and development-stage profile. Sector exposure overlaps in healthcare innovation, but JAZZ offers broader diversification and a more stable balance sheet with significant cash reserves. Market sentiment reflects analyst optimism for both, tempered by the distinct risk profiles of clinical versus commercial operations.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue stability, and near-term catalysts, Tickeron’s AI would currently assign a higher probabilistic preference to JAZZ. The company’s established commercial portfolio, positive earnings trajectory, and multiple regulatory milestones provide a more consistent foundation relative to AMLX’s reliance on future clinical outcomes. This assessment reflects relative positioning in the current environment rather than any definitive outlook.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and JAZZ is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMLX’s FA Score shows that 0 FA rating(s) are green whileJAZZ’s FA Score has 0 green FA rating(s).
- AMLX’s FA Score: 0 green, 5 red.
- JAZZ’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMLX’s TA Score shows that 4 TA indicator(s) are bullish while JAZZ’s TA Score has 4 bullish TA indicator(s).
- AMLX’s TA Score: 4 bullish, 4 bearish.
- JAZZ’s TA Score: 4 bullish, 4 bearish.
Price Growth
AMLX (@Pharmaceuticals: Generic) experienced а +10.75% price change this week, while JAZZ (@Biotechnology) price change was +2.19% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +3.42%. For the same industry, the average monthly price growth was -2.40%, and the average quarterly price growth was +25.94%.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.37%. For the same industry, the average monthly price growth was -6.07%, and the average quarterly price growth was +2852.75%.
Reported Earning Dates
AMLX is expected to report earnings on Aug 06, 2026.
JAZZ is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+3.42% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (+3.37% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AMLX | JAZZ | AMLX / JAZZ | |
| Capitalization | 2.43B | 17B | 14% |
| EBITDA | -158.8M | 675M | -24% |
| Gain YTD | 80.877 | 53.865 | 150% |
| P/E Ratio | 2.69 | 17.57 | 15% |
| Revenue | 0 | 4.44B | - |
| Total Cash | 280M | 2.87B | 10% |
| Total Debt | 5.63M | 5.42B | 0% |
JAZZ | ||
|---|---|---|
OUTLOOK RATING 1..100 | 84 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 53 | |
SMR RATING 1..100 | 91 | |
PRICE GROWTH RATING 1..100 | 37 | |
P/E GROWTH RATING 1..100 | 35 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AMLX | JAZZ | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 72% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 61% |
| Momentum ODDS (%) | 2 days ago 79% | 2 days ago 66% |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 71% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 84% | 2 days ago 66% |
| Advances ODDS (%) | 8 days ago 80% | 10 days ago 60% |
| Declines ODDS (%) | 4 days ago 81% | 4 days ago 55% |
| BollingerBands ODDS (%) | 2 days ago 79% | 2 days ago 54% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 65% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MYMH | 24.44 | 0.01 | +0.06% |
| State Street® My2028 Municipal Bond ETF | |||
| UBND | 21.51 | 0.01 | +0.03% |
| VictoryShares Core Plus Bond ETF | |||
| TBT | 37.52 | -0.09 | -0.24% |
| ProShares UltraShort 20+ Year Treasury | |||
| ASMF | 25.57 | -0.16 | -0.61% |
| Virtus AlphaSimplex Managed Futures ETF | |||
| CARZ | 106.41 | -1.17 | -1.08% |
| First Trust S-Network Fut Vhcl&Tech ETF | |||
AMLX and
Correlation & Price change
A.I.dvisor indicates that over the last year, AMLX has been loosely correlated with OCUL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AMLX jumps, then OCUL could also see price increases.
| Ticker / NAME | Correlation To AMLX | 1D Price Change % | ||
|---|---|---|---|---|
| AMLX | 100% | -0.09% | ||
| OCUL - AMLX | 46% Loosely correlated | -1.05% | ||
| LRMR - AMLX | 45% Loosely correlated | -0.24% | ||
| JAZZ - AMLX | 43% Loosely correlated | -0.02% | ||
| RGNX - AMLX | 43% Loosely correlated | +1.94% | ||
| IDYA - AMLX | 43% Loosely correlated | -0.19% | ||
More | ||||